Influx Healthtech Earnings Call Transcript: Key Takeaways
Revenue rose 27.9% to ₹85.4 Cr, but EBITDA and PAT margins both contracted, and capex of ₹19.9 Cr far exceeds ₹7.2 Cr operating cash flow.
- Call
- Guides 25% growth
ALFA Filings
Every announcement, straight from the exchange
Every earnings call announcement on NSE and BSE that our alert engine sent, newest first. Each one has its own page with the summary, the key figures and the original filing.
Time
2,456 announcements with these filters
Revenue rose 27.9% to ₹85.4 Cr, but EBITDA and PAT margins both contracted, and capex of ₹19.9 Cr far exceeds ₹7.2 Cr operating cash flow.
Standalone PAT fell 33% YoY to ₹87 Cr and EBITDA fell 27% despite 21% higher income. Management blamed Middle East-driven energy and logistics costs and ATBS customer destocking.
Q2 FY27 consolidated revenue ₹10,225Mn (+26.8%), PAT ₹922Mn (+64.1%), EBITDA margin 17.0%. Record order book ₹226,811Mn; HAM monetisation and entry into transmission.
H1 FY27: AUM ₹326.4bn (+20% adj. YoY), PAT ₹5.9bn (+22% adj.; reported +17%), GNPA 1.3%, ROA 4.2%. Spreads stable at 5.7%.
Q2 FY27 revenue ~INR 1,576 Cr (+10%+), EBITDA INR 207 Cr; H1 revenue ~INR 3,100 Cr (+4%). Cash-focused: working capital cycle cut to 179 days; drought and polymer costs weigh on H2.
Q2 FY27 revenue ₹386 Cr (+18.8% YoY), adjusted EBITDA ₹71 Cr at 18.2%, PAT ₹36 Cr. Management steers investors away from PAT, avoids forward numbers, and leans on superlatives.
Record Q2 revenue of ₹538 Cr (+35%) and EBITDA of ₹151 Cr (28% margin), but gross margin fell roughly 700 bps and management deflected several key questions.
Standalone revenue grew 18.9% but PBDIT only 4.9%, as raw-material inflation of about 25% outran 7-8% price hikes. Management deflects to 'sequential improvement' rather than quantifying margin recovery.
Q2 FY27 standalone: total income Rs339.3cr (+8.8% YoY), EBITDA Rs43.0cr (12.7% margin), PAT Rs26.7cr (+6.0%). Strategy centres on multimodal expansion, automation and capex.
Q2FY27 revenue INR 581.5 mn (+51% QoQ), PAT INR 41.2 mn (+238% QoQ), EBITA INR 81.88 mn (+74% QoQ). Growth led by North America; defence shell programmes progressing.
Q2 FY27 revenue rose 30% to ₹661 Cr at a 12.8% EBITDA margin. H1 operating cash flow of ₹56 Cr is reported, and management highlights ₹125 Cr excluding a ₹68 Cr payables payment. Order book is ₹3,093 Cr, but H1 volumes fell about 13%.
Q2 revenue rose 16.9% to ₹452 Cr, but EBITDA margin fell to 13.5% and gross margin dropped to 51.4%. The FY27 17% EBITDA margin target needs a sharp H2 recovery.
Q2/H1 FY27 deck; no quarterly revenue, PAT or EBITDA disclosed. Highlights FY23–FY26 margin gains and H1 FY27 field-activity metrics.
Q2 FY27: revenue from operations ₹9,385 Mn (+13.0% YoY), EBITDA ₹1,187 Mn (-7.4%), PAT ₹690 Mn (-11.2%), EBITDA margin 12.6%. Ethnic snacks +19.7%.
Q2 FY27 revenue ₹902.6 Cr (+77% QoQ, +17.5% YoY), PAT ₹20.2 Cr, EBITDA margin 7.7%. Odisha integrated cell-module expansion is ramping.
Q2 FY27 revenue ₹5,764Mn (+39.9%), EBITDA ₹1,464Mn (+54.1%, 25.4% margin), PAT ₹904Mn (+67.9%). Arinna consolidated; FY27 margin guidance raised to 24%+.
Record Q2 revenue of ₹318 Cr (+17% YoY) and H1 EBITA margin up to 7.8%, but the Mahad plant drag, weak camphor volumes and undisclosed Unilever terms temper the story.
H1 FY27 Group total income Rs 60,356 Mn, adj EBITDA Rs 8,720 Mn (14%), adj PAT Rs 452 Mn after Molycop grinding media loss. Tega ex-Molycop adj PAT Rs 602 Mn.
Q2 revenue ₹6,655 Cr (+38%), EBITDA ₹733 Cr at 11% margin, PAT ₹420 Cr (+38%). Casting growth partly reflects metal price pass-through, and net debt rose to ₹2,415 Cr.
Q2 FY27 operating revenue rose 13% YoY; EBITDA INR708m (3.2% margin) and PAT INR456m. FIFA-driven digital surge, but margins were hit by sports and new-initiative spends.
Q2 FY27 revenue Rs3,757mn (record, +127% YoY), EBITDA Rs1,188mn (31.6%), PAT Rs1,025mn (27.3%). H1 FY27 revenue Rs6,689mn, PAT Rs1,808mn. Growth led by pharma intermediates and API.
H1FY27 revenue ₹980 Cr (+52%), EBITDA ₹98 Cr (10% margin), PAT ₹69 Cr (+56%). Q2 revenue +50% but EBITDA margin compressed to 6.6%.
Q2 FY27 consolidated revenue ₹5,686 Cr (+6%), EBITDA flat at ₹1,217 Cr, PAT ₹438 Cr (-2%). Acquiring 1.4 GWp ReNew solar portfolio at ₹4,859 Cr EV, targeting 10 GW renewables.
Q2FY27 consolidated revenue ₹2,280 Cr (+43% YoY), EBITDA ₹77 Cr (3.39% margin), PAT ₹46.2 Cr (+57%), a record quarter. Steel volumes 3.03 lakh tonne (+27%). Strategy: steel volume thrust plus non-steel build-out.
Q2 revenue +65% to ₹554 Cr and habitat +58%, helped by the Perundurai restart. H1 growth is price-led. Management gave no quantified FY27 guidance and avoided numbers on margins and capex.
Record ₹771 Cr Q2 revenue (+19%) masks a profit decline: PAT ₹48 Cr vs ₹51 Cr, and EBITDA margin of 15.5% sits at the guidance floor. Management called the analyst's contract-asset concern incorrect and gave no aging data on the call.
Q2 was muted: revenue milestones slipped 10-15 days into Q3, hitting top and bottom line. Management reiterates FY27 double-digit revenue growth and margin red lines, with no quantified Q2 numbers given.
Q2 FY27 profit rose 16% QoQ to ₹201 Cr as pre-tax margin widened to 23%. Management guides above ₹800 Cr PAT for FY27. Bounce-rate and 30+ DPD questions were not answered with figures.
Headline revenue growth of 36% flatters the quarter: like-to-like growth was 24%, gross margin fell 520 bps, and PAT fell 3% on tax normalisation.
Strong Q2 pre-sales (₹2,100 Cr, 274 units) but thin reported P&L: revenue ₹52.5 Cr, PAT ₹4.7 Cr, pending handovers.